Ulotaront lacks a direct antagonistic effect on dopamine D2 receptors [8] and, thus, emerges as the first antipsychotic drug effective clinically in schizophrenia without side effects caused by the blockade of D2 dopamine receptors, such as increased weight, elevated prolactin and glucose or development of EPS [9]. Here, DRD2 is linked to schizophrenia.